Short Interest in BlackRock Health Sciences Term Trust (NYSE:BMEZ) Decreases By 7.4%

BlackRock Health Sciences Term Trust (NYSE:BMEZ) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 79,800 shares, a decline of 7.4% from the September 30th total of 86,200 shares. Based on an average daily trading volume, of 195,000 shares, the days-to-cover ratio is presently 0.4 days.

Insider Transactions at BlackRock Health Sciences Term Trust

In other BlackRock Health Sciences Term Trust news, major shareholder Saba Capital Management, L.P. purchased 15,455 shares of BlackRock Health Sciences Term Trust stock in a transaction on Thursday, September 19th. The shares were bought at an average price of 16.14 per share, with a total value of 249,443.70. Following the purchase, the insider now directly owns 20,601,568 shares in the company, valued at 332,509,307.52. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders bought a total of 99,630 shares of company stock worth $1,585,113 over the last ninety days.

Institutional Trading of BlackRock Health Sciences Term Trust

A number of institutional investors have recently modified their holdings of BMEZ. Almitas Capital LLC grew its stake in BlackRock Health Sciences Term Trust by 89.3% during the second quarter. Almitas Capital LLC now owns 1,761,943 shares of the company’s stock worth $27,063,000 after buying an additional 831,025 shares during the period. Commonwealth Equity Services LLC increased its holdings in BlackRock Health Sciences Term Trust by 4.1% in the 1st quarter. Commonwealth Equity Services LLC now owns 142,038 shares of the company’s stock valued at $2,328,000 after purchasing an additional 5,537 shares in the last quarter. Comerica Bank lifted its stake in shares of BlackRock Health Sciences Term Trust by 31.1% during the first quarter. Comerica Bank now owns 15,469 shares of the company’s stock worth $254,000 after purchasing an additional 3,671 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in shares of BlackRock Health Sciences Term Trust by 11.2% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 65,088 shares of the company’s stock worth $1,000,000 after buying an additional 6,565 shares during the period. Finally, Dakota Wealth Management grew its stake in shares of BlackRock Health Sciences Term Trust by 5.3% in the second quarter. Dakota Wealth Management now owns 18,242 shares of the company’s stock valued at $280,000 after buying an additional 915 shares in the last quarter.

BlackRock Health Sciences Term Trust Price Performance

Shares of BMEZ traded up 0.13 during mid-day trading on Friday, hitting 15.56. The company had a trading volume of 43,020 shares, compared to its average volume of 264,645. BlackRock Health Sciences Term Trust has a 1-year low of 13.25 and a 1-year high of 16.59. The business’s 50-day simple moving average is 15.83 and its 200-day simple moving average is 15.48.

BlackRock Health Sciences Term Trust Announces Dividend

The company also recently declared a monthly dividend, which was paid on Thursday, October 31st. Shareholders of record on Tuesday, October 15th were given a dividend of $0.176 per share. This represents a $2.11 dividend on an annualized basis and a yield of 13.57%. The ex-dividend date of this dividend was Tuesday, October 15th.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Trust II’s (BMEZ) (the ‘Trust’) investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust seeks to achieve its investment objective by investing, under normal market conditions, at least 80% of its total assets in equity securities of companies principally engaged in the health sciences group of industries and equity derivatives with exposure to the health sciences group of industries.